Combination therapy with methylprednisolone,rituximab,and tofacitinib in antimelanoma differentiation-associated 5 gene dermatomyositis with rapidly progressive interstitial lung disease  

作　　者：Mona Manghani Weiyen Lim Gin Tsen Chai Xin Rong Lim Choon Guan Chua 

机构地区：[1]Department of Rheumatology,Allergy and Immunology,Tan Tock Seng Hospital,Singapore City,Singapore [2]Department of Preventative and Population Medicine,Tan Tock Seng Hospital,Singapore City,Singapore [3]Department of Respiratory Medicine,Tan Tock Seng Hospital,Singapore City,Singapore Department of Respiratory Medicine,Tan Tock Seng Hospital,Singapore City,Singapore

出　　处：《Rheumatology & Autoimmunity》2024年第2期122-125,共4页风湿病与自身免疫（英文）

摘　　要：To the Editor,Anti-melanoma differentiation-associated gene 5(anti-MDA5)antibody-associated dermatomyositis(DM)presenting with rapidly progressive interstitial lung disease(RP-ILD)is extremely challenging to treat.MDA5 is a cytosolic viral RNA sensor that normally triggers an innate response resulting in interferon I production.Upregulation of MDA5 expression can result in autoantibody formation,leading to overactivation of the type I interferon pathway,causing aberrant metabolic remodeling of peripheral B and T cells and a profibrotic response in the affected lungs.

关 键 词：INTERFERON melanoma lung 

分 类 号：R593.26[医药卫生—内科学]